Smyth J F, Smith I E, Sessa C, Schoffski P, Wanders J, Franklin H, Kaye S B
University Department of Clinical Oncology, Western General Hospital, Edinburgh, U.K.
Eur J Cancer. 1994;30A(8):1058-60. doi: 10.1016/0959-8049(94)90455-3.
Docetaxel (Taxotere) is a new cytotoxic compound with a broad spectrum of activity in preclinical studies. This paper reports a phase II trial in patients with previously-treated small cell carcinoma of the lung. 34 patients received 100 mg/m2 of docetaxel in an intravenous infusion given over 1 h every 21 days. Seven partial responses were reported (25% of 28 evaluable patients). Duration of response was 3.5-12.6 months. Toxicities were predominantly neutropenia, alopecia and asthenia. Docetaxel is a new compound with activity in previously-treated patients with small cell lung cancer, and is suitable for evaluation in combination with other cytotoxic drugs active in this disease.
多西他赛（泰索帝）是一种新型细胞毒性化合物，在临床前研究中具有广泛的活性。本文报道了一项针对既往治疗过的小细胞肺癌患者的II期试验。34例患者每21天接受一次静脉输注多西他赛，剂量为100mg/m²，输注时间为1小时。据报道有7例部分缓解（28例可评估患者中的25%）。缓解持续时间为3.5至12.6个月。毒性主要为中性粒细胞减少、脱发和乏力。多西他赛是一种对既往治疗过的小细胞肺癌患者有活性的新型化合物，适用于与该疾病中其他有活性的细胞毒性药物联合进行评估。
